Burden of severe neonatal jaundice: a systematic review and meta-analysis

Tina M Slusher,^{1,2} Tara G Zamora,¹ Duke Appiah,³ Judith U Stanke,⁴ Mark A Strand,⁵ Burton W Lee,⁶ Shane B Richardson,⁷ Elizabeth M Keating,⁸ Ashajoythi M Siddappa,^{1,2} Bolajoko O Olusanya⁹

To cite: Slusher TM, Zamora TG, Appiah D, *et al*. Burden of severe neonatal jaundice: a systematic review and meta-analysis. *BMJ Paediatrics Open* 2017;1:e000105. doi:10.1136/bmjpo-2017-000105

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjpo-2017-000105>).

Received 26 May 2017
Revised 25 September 2017
Accepted 1 October 2017

CrossMark

¹Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA

²Hennepin County Medical Center, Minneapolis, Minnesota, USA

³Texas Tech University Health Science Center, Abilene, Texas, USA

⁴Biomedical Library, University of Minnesota, Minneapolis, Minnesota, USA

⁵Department of Pharmacy, North Dakota State University, Fargo, North Dakota, USA

⁶Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

⁷Department of Family Medicine, University of Arizona, Tucson, Arizona, USA

⁸Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA

⁹Center for Healthy Start Initiative, Lagos, Nigeria

Correspondence to

Dr Tina M Slusher; tslusher@umn.edu

ABSTRACT

Context To assess the global burden of late and/or poor management of severe neonatal jaundice (SNJ), a common problem worldwide, which may result in death or irreversible brain damage with disabilities in survivors. Population-based data establishing the global burden of SNJ has not been previously reported.

Objective Determine the burden of SNJ in all WHO regions, as defined by clinical jaundice associated with clinical outcomes including acute bilirubin encephalopathy/kernicterus and/or exchange transfusion (ET) and/or jaundice-related death.

Data sources PubMed, Scopus and other health databases were searched, without language restrictions, from 1990 to 2017 for studies reporting the incidence of SNJ.

Study selection/data extraction Stratification was performed for WHO regions and results were pooled using random effects model and meta-regression.

Results Of 416 articles including at least one marker of SNJ, only 21 reported estimates from population-based studies, with 76% (16/21) of them conducted in high-income countries. The African region has the highest incidence of SNJ per 10 000 live births at 667.8 (95% CI 603.4 to 738.5), followed by Southeast Asian, Eastern Mediterranean, Western Pacific, Americas and European regions at 251.3 (132.0 to 473.2), 165.7 (114.6 to 238.9), 9.4 (0.1 to 755.9), 4.4 (1.8 to 10.5) and 3.7 (1.7 to 8.0), respectively. The incidence of ET per 10 000 live births was significantly higher for Africa and Southeast Asian regions at 186.5 (153.2 to 226.8) and 107.1 (102.0 to 112.5) and lower in Eastern Mediterranean (17.8 (5.7 to 54.9)), Americas (0.38 (0.21 to 0.67)), European (0.35 (0.20 to 0.60)) and Western Pacific regions (0.19 (0.12 to 0.31)). Only 2 studies provided estimates of clear jaundice-related deaths in infants with significant jaundice [UK (2.8%) and India (30.8%).

Conclusions Limited but compelling evidence demonstrates that SNJ is associated with a significant health burden especially in low-income and middle-income countries.

INTRODUCTION

Newborn jaundice occurs in up to 85% of all live births.^{1–3} In the absence of haemolysis, sepsis, birth trauma or prematurity, it usually resolves within 3–5 days without significant complications.¹ However, epidemiological

What is already known on this topic?

- Acute bilirubin encephalopathy (ABE), exchange transfusions and death are frequent and costly outcomes of severe neonatal jaundice (SNJ) especially in low-income and middle-income countries.
- Long-term disabilities including cerebral palsy and deafness can occur following ABE.
- The actual burden of SNJ is not well documented.

What this study hopes to add?

- A review of population-based literature to assess the global impact of severe neonatal jaundice (SNJ) highlighting the importance of this disease as defined by its clinical presentations.
- Objective evidence that the burden of SNJ is not evenly distributed and that a heavier burden of disease is born by low-income and middle-income countries.
- The limited amount of population-based data currently available and the need to capture this information globally.

evidence suggests that severe neonatal jaundice (SNJ) results in substantial morbidity and mortality.⁴ SNJ has been recognised as a significant cause of long-term neurocognitive and other sequelae, cerebral palsy, non-syndromic auditory neuropathy, deafness and learning difficulties.^{5 6} The burden is unacceptably high in low-income and middle-income countries (LMICs) and has prompted calls for intense scrutiny and attention.⁴ Under the millennium development goals, the potential impact of adverse perinatal conditions such as preterm birth complications and birth asphyxia on thriving and well-being beyond survival rarely received attention.⁷ With the current focus on inclusiveness for persons with disability under the sustainable development goals (SDGs), it is essential that we tackle SNJ as one key component of optimising neurodevelopmental outcome.^{7 8}

A recent report by Bhutani *et al*⁴ noted that at least 481 000 term/near-term neonates are affected by SNJ/hyperbilirubinaemia each year, with 114 000 dying and an additional 63 000 surviving with kernicterus. However, these alarming estimates were based on limited data determined by mathematical modelling as true population-based data are limited and difficult to find. Therefore, the incidence of SNJ and thus its contribution to global neonatal morbidity and mortality presently remain unclear and possibly significantly underestimated.

Jaundice is usually recognised around a total serum bilirubin (TSB) of 5 mg/dL in neonates.³ SNJ is unlikely to happen before a TSB of at least 20–25 mg/dL in term neonates presenting early.⁴ TSB is unfortunately often either not available or delayed in many LMICs.⁹ Therefore, for the purposes of this article, severe SNJ is defined as jaundice associated with acute bilirubin encephalopathy (ABE)/kernicterus and/or exchange transfusions (ET) and/or jaundice-related death.

Phototherapy and ET are widely used therapeutic modalities for jaundice.² However, due to constrained resources, devices for measuring bilirubin^{10 11} and effective phototherapy are often lacking in LMICs.¹² This, together with higher prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency, blood group incompatibilities, late referrals and delayed recognition of excessive bilirubin levels in LMICs, has necessitated excessive use of ETs.¹³

We systematically reviewed the available evidence pertaining to the global burden of SNJ to inform child health policy regarding its prevention and management especially in LMICs.

METHODS

Search criteria

Although most SNJ occurs at TSB at 20 mg/dL (343 µmol/L), there is no standard worldwide definition of SNJ or clinically significant TSB necessitating medical intervention. There is a wide range of definitions of significant jaundice. In studies reviewed in this article, TSB levels considered significant, when results were available, generally ranged from 15 to 30 mg/dL.^{14–27} Even though beginning in 2004, the American Academy of Pediatrics recommended ABE be used for acute manifestations of SNJ in the first weeks of life and kernicterus for chronic manifestations of SNJ/ABE,²⁸ many still use the terms interchangeably. Because of limited availability of TSBs and our attempt to quantify the burden of clinical disease, we defined SNJ clinically using ABE, ET and jaundice-related death.

We systematically reviewed published papers following PRISMA guidelines (online supplementary appendix 1).¹³ Databases searched included Ovid Medline, PubMed, CINAHL, Global Health, Scopus, Popline, Africa Journal Online and Bioline databases for published articles on SNJ. We used both controlled subject headings and free-text terms for neonatal jaundice (NNJ), jaundice,

bilirubin/blood levels, haemolytic anaemia, G6PD deficiency in various forms and in combination with terms for ET, ABE, kernicterus, death, mortality and phototherapy. Other inclusion criteria were jaundice in first month of life; availability of data on incidence of ABE/kernicterus; provision of information on incidence of ETs for SNJ or jaundice-related death which we defined as SNJ. We also reviewed references of selected retrieved articles and review papers, and contacted authors of relevant articles for missing dates. No language restrictions were used. To be included in the meta-analysis, a study must have reported estimates of incidence from a retrospective or prospective population-based study, increasing likelihood that estimates could be generalised to the geographical location where the study was conducted. The search results were limited to publication dates of 1990 to June 2017. See online supplementary appendix 2 for complete Ovid Medline search strategy.

Data extraction

Two authors examined studies using a predetermined checklist (online supplementary appendix 3) devised by three authors for selecting articles that met inclusion criteria after one author screened titles and abstracts. Two authors independently confirmed eligibility of all full-text articles. Discrepancies were resolved by discussion and when needed by a third author. The following data were extracted from each article: publication year, study design, country, WHO region, sample size, SNJ definition and outcomes (ET, ABE, mortality). Articles were excluded if neonates were enrolled before 1990; study published after June 2017; sample size <10; ET unrelated to SNJ, results limited to only metabolic or primary liver diseases, studies with defined enrolment period, failure to define neonates as having ABE, ET or jaundice-related death and for the meta-analysis if they included only premature neonates.

Quality assessment

We explored several quality assessment tools reported in the literature for observational studies including the Newcastle-Ottawa Scale,²⁹ and found none directly applicable for evaluating diagnostic studies on NNJ/hyperbilirubinaemia. We therefore chose to adopt the tool validated by Wong *et al*³⁰ with all the critical components for assessing the risk of bias across studies. Two authors examined four important components of quality/risk of bias assessment: selection of subjects (representativeness), case definition for SNJ (exposure ascertainment), diagnostic criteria for jaundice and outcome measurement. Study quality was judged based on number of criteria that were met: all 4 (high), 2–3 (medium) or 1 (low). Finally, two authors determined which studies were population-based. We defined population-based studies as studies that addressed the incidence of SNJ for a defined population with every individual in the population having the same probability of being in the study and the results of the study having the ability to

Figure 1 Flow chart of study selection for the meta-analysis.

be generalisable to the whole population from which study participants were sampled and not necessarily the individuals included in the study.³¹ Disagreements were resolved through consensus after joint reassessment.

Statistical analysis

For the meta-analysis, when multiple reports were obtained from the same population with overlapping study years, the one providing sufficient data (ie, numerator and denominator data) to derive estimates of disease burden was selected. To facilitate meta-analytical techniques, estimates of incidence were logit transformed to enable them to correspond to probabilities under the standard normal and permit use of the normal distribution for significance testing. Pooled estimates were calculated using DerSimonian and Laird's random effects method, weighting individual study estimates by the inverse of the variance of their transformed proportion as study weight, with their 95% (CI) determined using Clopper-Pearson exact binomial method.³² For presentation, pooled transformed estimates were back transformed. Statistical heterogeneity among studies was investigated using Cochran's Q test and I^2 with a conservative p value less than 0.1 chosen as the level of significance. Forest plots were then used to examine the overall effects. Exploration of potential sources of heterogeneity was undertaken using meta-regression. Whether it is an interventional or an observational study, small studies are

more likely to show more extreme values given wider CIs compared with larger studies. Since more extreme findings may be more newsworthy and hence more likely to be published, potential for publication bias was assessed by visual inspection of the funnel plot as well as by formal means using Begg's adjusted rank correlation and Egger's regression asymmetry tests.³³ All analyses were conducted using R Statistical Software.³⁴

RESULTS

Search of electronic databases identified 6844 articles (figure 1). Eight hundred and twenty papers were reviewed. After excluding studies not meeting inclusion criteria, 416 studies were selected for further review. Multiple languages (Chinese, English, Farsi, French, German, Hebrew, Italian, Norwegian, Polish, Portuguese, Serbian and Spanish) were represented, with translation of relevant sections, but only 26/416 were non-English, none of which were population based. Of these, 416 papers included at least one marker of SNJ, but only 21 provided population-based data on 4 975 406 neonates (table 1).

Sixteen (76%) were from high-income countries and 13 (62%) used a prospective study design. High-quality studies tended to report lower incidence compared with low-quality to moderate-quality studies (figure 2). High-quality studies tended to come from high-income countries with less disease while low-quality studies tend to come from LMICs. Overall, incidence estimates of SNJ from high-income countries tended to be lower compared with LMICs (figure 3). Studies which enrolled all neonates regardless of gestational age had a higher incidence of SNJ compared with studies enrolling only term/near-term (table 2).

The incidence of SNJ per 10 000 live births was highest in the African region at 667.8, followed by Southeast Asian at 251.3, Eastern Mediterranean with 165.7 and Western Pacific region with 9.4. The Americas and European regions each had substantially lower incidence of 4.4 and 3.2, respectively (table 3).

The incidence of ET per 10 000 live births was significantly higher for the African (186.5) and Southeast Asian (107.1) regions and lower in Eastern Mediterranean, Americas, European and Western Pacific regions reporting estimates of 17.8, 0.38, 0.35 and 0.19, respectively (table 4).

Visual inspection of funnel plot in which incidences of SNJ were plotted against their standard errors showed asymmetry. This was confirmed by formal tests of publication bias (Begg-Mazumdar test: $p=0.016$, Egger: bias, $p=0.002$). The observed heterogeneity between studies may explain the asymmetric funnel plots. In random effects meta-regression analyses, the overall observed between-study heterogeneity explained by covariates which were selected a priori (study design and duration, income classification of country and gestational age) was 66.23%; $p<0.001$. However, only income classification of country was statistically significant determinant of the incidence of SNJ (table 5). Only two

Table 1 Studies that met the inclusion criteria to be included in the meta-analysis

Study	Continent	WHO region	Country	Duration (years)	Live births	Study design	Sample description	Income class	Quality score	Definition of jaundice and clinical indicators
Bang <i>et al</i> ³⁵	Asia	Southeast Asia	India	1	763	P	All neonates	Low-middle	2	Deaths from NNU
Bhutani <i>et al</i> ¹⁴	North America	Americas	USA	5	2 935 674	R	Term and near term	High	3	Both ET and TSB >25 mg/dL TSB >30 mg/dL
Bjerre <i>et al</i> ¹⁵	Europe	Europe	Denmark	3	249 308	R	Term and near term	High	3	TSB ≥510 µmol/L (30 mg/dL), ABE, ET
Christensen <i>et al</i> ¹⁶	North America	Americas	USA	10	302 399	R	All neonates	High	4	TSB >25 mg/dL, TSB >30 mg/dL, ABE, ET
Ebbesen <i>et al</i> ¹⁷	Europe	Europe	Denmark	2	128 344	P	Term and near term	High	3	TSB>ET indicated, ABE
Ebbesen <i>et al</i> ³⁸	Europe	Europe	Denmark	8	502 766	P	Term and near term	High	3	TSB >450 µmol/L (26 mg/dL), ABE
Eggert <i>et al</i> ¹⁸	North America	Americas	USA	3.8	101 272	R	Term and near term	High	3	TSB >20 mg/dL, TSB ≥25 mg/dL ABE, ET
Flaherman <i>et al</i> ¹⁹	North America	Americas	USA	3	18 089	R	Term and near term	High	3	TSB>ET indicated
Gotink <i>et al</i> ²⁰	Europe	Europe	Netherlands	5	683 048	P	Term and near term	High	4	TSB >500 µmol/L (29 mg/dL) or received ET+TSB > 340 µmol/L (20 mg/dL), ET+TSB >430 µmol/L (25 mg/dL), ABE
Kuzniewicz <i>et al</i> ⁴⁰	North America	Americas	USA	17	525 409	R	Term and near term	High	3	TSB ≥25 mg/dL, ET
Le <i>et al</i> ³⁷	Asia	Western Pacific	Vietnam	2	979	R	All neonates	Low-middle	2	Need for PT, ET, kernicterus, death
Manning <i>et al</i> ²²	Europe	Europe	UK	3	1 500 052	P	All neonates	High	4	TSB >510 µmol/L (30 mg/dL), ABE, death
McGillivray <i>et al</i> ²³	Australia	Western Pacific	Australia	3	893 893	P	Term and near term	High	3	TSB >450 µmol/L (26 mg/dL), ABE signs, ET
Meberg and Johansen ²⁴	Europe	Europe	Norway	1	2424	P	All neonates	High	4	TSB >350 µmol/L (20 mg/dL), ET, ABE
NNDP database ²⁵	Asia	Southeast Asia	India	2	145 623	P	All neonates	Low-middle	4	TSB >15 mg/dL, ET
Olusanya <i>et al</i> ²²	Africa	Africa	Nigeria	2	5256	R	All neonates	Low-middle	2	PT, ET
Sgro <i>et al</i> ²⁶	North America	Americas	Canada	2	639 840	P	Term	High	3	TSB >425 µmol/L (25 mg/dL), ET
Sgro <i>et al</i> ⁷⁸	North America	America	Canada	2	760 000	P	Term	High	3	TSB >425 µmol/L, or ET, ABE symptoms
Tikmani <i>et al</i> ³	Asia	Eastern Mediterranean	Pakistan	2	1690	P	All neonates	Low-middle	4	Referred for jaundice, >15 mg/dL, ET
Wainer <i>et al</i> ³⁸	North America	Americas	Canada	2	21 856	P	Term and near term	High	3	TSB >342 µmol/L (20 mg/dL) 427 µmol/L (25 mg/dL), ≥513 µmol/L (30 mg/dL), ET
Zoubir <i>et al</i> ²⁷	Europe	Europe	Switzerland	2	146 288	P	All neonates	High	3	TSB>ET, ET

ABE, acute bilirubin encephalopathy; ET, exchange transfusion; NNU, neonatal jaundice; PT, phototherapy; TSB, total serum bilirubin.

Figure 2 Pooled incidence (per 10 000) of severe neonatal jaundice among all neonates aged 24 months or less according to study quality.

studies provided information on jaundice-related deaths with estimates of 2.8, 30.8 and 50.0 for UK (European),²² and India (Southeastern)³⁵ While one study from Pakistan³ (Eastern Mediterranean), mentions death in 30% of infants with jaundice but stated they did not feel the deaths could be directly attributed to jaundice.

DISCUSSION

Although data are limited despite our extensive literature review, this systematic review and meta-analysis suggests that the incidence of SNJ is high, with regions that include predominantly LMICs bearing the greatest burden of disease. In the systematic review, mentioned earlier by Bhutani *et al*⁴ 18% of 134 million live births had SNJ with the greatest burden of disease in LMICs, and therefore supporting this hypothesis. But as previously pointed out, these estimates were generated by mathematical modelling due to lack of accurate incidence data available. Both Bhutani's data as well as this review, highlight the glaring paucity of studies particularly in LMICs. Although all WHO regions are represented, only 4/136 (2.9%) LMICs countries were represented with most having only one study (India (Southeast) n=2,^{25 35} Nigeria (African) n=1³⁶ and Pakistan (Eastern Mediterranean) n=1,³ Vietnam (Western Pacific) n=1).³⁷ In contrast representation among high-income countries, while low was better with 8/79 (10.1%) high-income countries having population-based data (Australia (Western Pacific) n=1,²³ Canada (Americas) n=3,^{26 38} Denmark (European)

n=3,^{15 17 39} Norway (European) n=1,²⁴ Netherlands (European) n=1,²⁰ Switzerland (European) n=1,²⁷ USA (Americas) n=5,^{16 18 19 40} UK and Ireland (European) n=1).²² This general lack of population-based studies worldwide emphasises the need for more accurate data to determine the actual burden of disease.

Jaundice was the primary diagnosis in 17% of neonates ≤1 week in a hospital-based study in Kenya,⁴¹ and several other African-based studies demonstrate that SNJ commonly leads to hospital admissions.^{42–44} This pattern is also observed in Asia, including the Middle East.^{41 45–49}

Although not readily generalisable, all regions do have numerous hospital-based studies among the 416 articles with at least one clinical indicator of SNJ, highlighting the prevalence of SNJ among admissions. For some countries, such as the USA and many European nations where hospital birth is the norm, this data would more accurately reflect true population-based data. However, in LMICs where '60 million women give birth outside a facility' (2012)⁵⁰ and recorded data population data spares, hospital data cannot be assumed to reflect true population data. The higher incidence of home births correlates well with the much higher incidence of SNJ noted in the studies from the African, Southeast Asian and Eastern Mediterranean regions compared with substantially lower incidence noted in the regions of the Americas and Europe.

Figure 3 Pooled incidence (per 10 000) of severe neonatal jaundice among all neonates aged 24 months or less according to income.

Although only one study each from Africa and Eastern Mediterranean met the definition of population based, these two studies underscore the burden of ETs in LMICs with 186.5 and 107.1 ET's per 10 000 live births in stark contrast to the American and European regions with only 0.38 and 0.35 per 10 000 live births, respectively.

ET for SNJ

While many paediatricians and even neonatologists in high-income countries never perform an ET, physicians in LMICs continue to perform ETs on a regular basis.¹³

Although population-based data were available in only a few LMICs studies, other hospital-based studies support their findings. Of note again is the high prevalence of ETs, reported in studies from many LMIC (22%–86%), particularly Nigeria,^{36 51 52} India^{53 54} and Bolivia.⁵⁵

Access to ET, a proxy indicator of the magnitude of SNJ, is often limited in resource poor countries.^{13 56 57} Multiple studies have demonstrated early intervention including phototherapy and appropriate ET can prevent kernicterus.^{56 58 59} Despite benefits of ET, there are associated

Table 2 Incidence (per 10 000 live births) of severe neonatal jaundice among all neonates aged 24 months or less by gestation and study design

Characteristics	N	Live births	Incidence	95% CI
Gestation*				
All	9	2 642 234	37.8	6.9 to 205.4
Term and near term	10	5 522 699	4.0	1.9 to 8.8
Term only	2	1 399 840	2.2	0.7 to 7.2
Design†				
Prospective	13	5 426 387	9.7	1.7 to 53.8
Retrospective	8	4 138 386	10.3	1.3 to 80.4

*Test for subgroup differences (Cochran's Q=7.42, p=0.025).

†Test for subgroup differences (Cochran's Q=0.002, p=0.963).

N, no of studies.

Table 3 Incidence of severe neonatal jaundice per 10 000 live births, among all neonates aged 24 months or less

WHO region	N	Live births	Incidence*	95% CI
Overall†	21	9 564 773	9.9	2.8 to 35.6
African	1	5256	667.8	603.4 to 738.5
Americas	8	5 304 539	4.4	1.8 to 10.5
Eastern Mediterranean	1	1690	165.7	114.6 to 238.9
European	7	3 212 230	3.7	1.7 to 8.0
Southeast Asian	2	146386	251.3	132.0 to 473.2
Western Pacific	2	894672	9.4	0.1 to 755.9

*Test for subgroup differences (Cochran's Q=346.9, p<0.001).

†I²=99%, Cochran's Q=34 721, p<0.001.

N, no of studies.

Table 4 Incidence of exchange transfusions, per 10 000 live births, among all neonates aged 24 months or less

WHO region	N	Live births	Incidence*	95% CI
Overall†	16	9 437 479	8.4	2.7 to 25.7
African	1	5256	186.5	153.2 to 226.8
Americas	6	5 181 411	0.38	0.21 to 0.67
Eastern Mediterranean	1	1690	17.8	5.7 to 54.9
European	6	3 209 806	0.35	0.20 to 0.60
Southeast Asian	1	145 623	107.1	102.0 to 112.5
Western Pacific	1	893 693	0.19	0.12 to 0.31

*Test for subgroup differences (Cochran's Q=1501.2, p<0.001).

†I²=99%, Cochran's Q=8730.7, p<0.001.

N, no of studies.

complications¹³ making it important to provide effective phototherapy before ET is needed.⁶⁰

SNJ is significant due to the associated mortality, but some would argue even more so because of associated long-term morbidity especially in LMICs ill-equipped to handle these disabilities. Farouk *et al* reported abnormal neurological findings in almost 90% of infants returning for follow-up after ABE in their nursery.⁶¹ Olusanya and Somefun,⁶² reported ET as a risk factor for sensorineural hearing loss in their community-based study in Nigeria, as did da Silva *et al* in Brazil.⁶³

Contribution of SNJ to neonatal mortality

While only two studies in this review,^{22 35 64} provided information on clear jaundice-related deaths, other studies have shown striking numbers of jaundice-related deaths where it reportedly accounted for 34% of neonatal deaths in Port Harcourt Nigeria,⁵² 15% in Ile-Ife, Nigeria,⁶⁵ 14% in Kilifi District Kenya,⁶⁶ 6.7% in Cairo Egypt⁶⁷ and 5.5% in Lagos Nigeria.⁶⁸

Multiple factors contributing to kernicterus in LMICs and the need for solutions addressing these factors has been spelled out in articles by Olusanya *et al*⁶⁹ and Slusher *et al*² including the need for national guidelines,^{9 60} effective phototherapy, rapid reliable diagnostic tools, maternal and healthcare provider education.⁷⁰

Table 5 Meta-regression analysis potential factors* influencing the heterogeneity of incidence of severe neonatal jaundice

Variable	Coefficient	95% CI	p Value
Intercept	-6.55	-8.76 to 4.81	0.001
Study design	-0.48	-1.75 to 0.79	0.461
Study duration	-0.15	-0.32 to 0.03	0.100
Gestation	-0.18	-1.64 to 1.28	0.812
Income	3.59	1.79 to 5.38	0.001

*Study design (prospective vs retrospective); study duration (years); gestation (all vs term and near term); income (low vs high) based on World Bank classifications (<https://datahelpdesk.worldbank.org/knowledgebase/articles/906519>).

Contribution of SNJ to long-term disability

Current evidence indicates SNJ continues to contribute significantly to the burden of cerebral palsy, deafness and other auditory processing disorders.⁴ In India, Mukhopadhyay *et al*⁷¹ found an abnormal MRI or brain-stem auditory evoked response in 61% and 76%, respectively, of children who underwent ET. In Nigeria, Ayanniyi and Abdulsalam⁷² reported NNJ as the leading cause of cerebral palsy (39.9%) trumping birth asphyxia (26.8%), while Ogunlesi *et al*⁷³ also from Nigeria, reported cerebral palsy, seizure disorders and deafness as leading sequelae of ABE, occurring in 86.4%, 40.9% and 36.4%, respectively. Oztürk *et al* from Turkey,⁷⁴ observed a history of prolonged jaundice commonly in children affected with cerebral palsy. Summing up available estimates, a recent *Lancet* article by Lawn *et al*⁷⁵ indicts pathological hyperbilirubinaemia/jaundice in >114 000 deaths and states that there are >63 000 damaged survivors.

The increased global awareness of SNJ has led to improvement in some locations. One notable example of this is Myanmar where a package of services including a photoradiometer, education and intensive phototherapy decreased ET by 69%.⁷⁶ Another example is the development, ongoing testing and refinement of filtered sunlight phototherapy in areas without access to continuous electricity or intensive phototherapy.⁷⁷ Several studies have shown that maternal and health worker education, screening programmes^{14 18 28 38} and national guidelines⁷⁸ can and do improve outcomes and decrease the observed clinical sequelae of SNJ.^{14 38 78} Many programmes supported by groups such as WHO⁷⁹ and Essential Care for Every Baby⁸⁰ now strongly support screening for jaundice and highlight it as a danger sign needing urgent care. This increased focus and awareness on SNJ is beginning to lead to decreases of this problem even in LMICs where recent studies though not always population based are beginning to show decreases in severe sequela.⁷⁶

Some limitations of this comprehensive review should be noted, besides those inherent in meta-analysis.⁸¹ Only 12/195 sovereign nations⁸² are represented in the quantitative data. While highlighting one of the greatest problems in determining the actual burden of disease from SNJ, absence of data from other countries despite searching multiple databases limits generalisability of our findings. Another significant limitation is the marked variability in the actual focus of the articles. The populations studied, availability of a TSB, recommendations and methods of screening, differences in TSBs and many other variables of included articles span an extremely wide range. Finally, the initial search excluding articles by title was done by only one author and the auditory evoked brainstem response, which is rarely available in LMICs, where not included in the criteria for SNJ.

Despite these limitations, this review still fills critical holes in our knowledge about the true burden of disease from this devastating but preventable tragedy. To our knowledge, this is the first attempt to report the global

burden of SNJ derived from population-based studies. While providing strong evidence for the burden of disease, it highlights the notable lack of population-based data from most countries, especially LMICs where the disease is more prevalent and most devastating. The burden of SNJ and its acute and chronic ramifications establish a strong case for appropriate health education, routine screening, early diagnosis and effective treatment. The spectrum of disease crosses ethnic and socioeconomic boundaries, impacting children everywhere, and is a commonly encountered hospital diagnosis worldwide. SNJ may represent the most common unrecognised and/or under-reported neonatal cause of preventable brain damage.⁸³ More research with capacity building especially in LMICs and other areas where data are limited are needed to truly quantify the impact of this disease and to better understand how to integrate screening and therapy to eliminate this disease in the future.

CONCLUSION

Compelling but limited evidence from the literature demonstrates that SNJ is associated with a significant acute and chronic health burden, especially in LMICs. There is an urgent need to address this preventable disease in these regions, consistent with the inclusiveness advocated for erstwhile disadvantaged populations under the current SDGs dispensation.

Acknowledgements We thank Dr Vinod Bhutani, Ms. Judith Hall RNC-NIC, and Dr Mark Ralston for their edits to an earlier version of the manuscript. We also thank Dr Philip Fischer, MD, Dr Reza Khodavardian, Dr Janielle Nordell, Ms Ann Olthoff, RN, Dr Clydette Powell, Dr Hoda Pourhassan, Dr Maryam Sharifi-Sanjani, Ms Olja Šušilović, Dr Deborah Walker, Ms Allia Vaez and Ms Agnieszka Villanti, RN, for their help in the translation of foreign language literature used in this review. We also thank Ms Ayo Bode-Thomas, Dr Katie Durrwachter Erno, Mr Jeffrey Flores, Ms Judith Hall, RNC-NIC, Mr Jonathan Koffel, Ms Toni Okuyemi, Dr Mark Ralston, Mr Del Reed, Mr Paul Reid, Dr Yvonne Vaucher, Ms Mabel Wafula, Ms Katherine Warner, Dr Olga Steffens for their help in editing the article/tables including retrieving articles, verifying numbers, and managing Endnote.

Contributors TS and BOO conceptualised and designed the study, acquired data, analysed and interpreted data, supervised the study, drafted the manuscript and conducted a critical revision of the manuscript for intellectual content and approved the manuscript as submitted. TGZ conceptualised and designed the study, and assisted with acquiring data and approved the manuscript as submitted. AMS assisted in acquiring data and approved the manuscript as submitted. EMK and JUS were responsible for acquisition of data as well as providing administrative, technical and material support and approved the manuscript as submitted. SBR was responsible for acquisition of data, analysing and interpreting data and provided administrative, technical and material support and approved the manuscript as submitted. DA, MAS and BWL analysed and interpreted the data, conducted the statistical analysis, and conducted a critical revision of the manuscript for important intellectual content and approved the manuscript as submitted. All authors had full access to all data, take responsibility for the accuracy and integrity of the data and approved the manuscript as submitted.

Funding Support for the quantitative analysis was provided in part by The Programme for Global Paediatric ReSouth-East Asianrch, Centre for Global Child Health, The Hospital for Sick Children, Toronto, Canada.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially,

and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. National Institutes for Health and Clinical Excellence. Neonatal jaundice. (clinical guidelines 98), 2010.
2. Slusher TM, Zipursky A, Bhutani VK. A global need for affordable neonatal jaundice technologies. *Semin Perinatol* 2011;35:185–91.
3. Tikmani SS, Warraich HJ, Abbasi F, et al. Incidence of neonatal hyperbilirubinemia: a population-based prospective study in Pakistan. *Trop Med Int Health* 2010;15:502–7.
4. Bhutani VK, Zipursky A, Blencowe H, et al. Neonatal hyperbilirubinemia and rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. *Pediatr Res* 2013;74:86–100.
5. Mwaniki MK, Atieno M, Lawn JE, et al. Long-term neurodevelopmental outcomes after intrauterine and neonatal insults: a systematic review. *Lancet* 2012;379:445–52.
6. Shapiro SM. Bilirubin toxicity in the developing nervous system. *Pediatr Neurol* 2003;29:410–21.
7. Lawn JE, Blencowe H, Darmstadt GL, et al. Beyond newborn survival: the world you are born into determines your risk of disability-free survival. *Pediatr Res* 2013;74 Suppl 1:1–3.
8. Tardi R, Njelesani J. Disability and the post-2015 development agenda. *Disabil Rehabil* 2015;37:1496–500.
9. Olusanya BO, Ogunlesi TA, Slusher TM. Why is kernicterus still a major cause of death and disability in low-income and middle-income countries? *Arch Dis Child* 2014;99:1117–21.
10. Mbwele B, Reddy E, Reyburn H. A rapid assessment of the quality of neonatal healthcare in Kilimanjaro region, northeast Tanzania. *BMC Pediatr* 2012;12:182.
11. Jirapaet K. Thai healthy newborns have a higher risk. *J Med Assoc Thai* 2005;88:1314–8.
12. Bhutani VK, Cline BK, Donaldson KM, et al. The need to implement effective phototherapy in resource-constrained settings. *Semin Perinatol* 2011;35:192–7.
13. Mabogunje CA, Olaifa SM, Olusanya BO. Facility-based constraints to exchange transfusions for neonatal hyperbilirubinemia in resource-limited settings. *World J Clin Pediatr* 2016;5:182–90.
14. Bhutani VK, Meng NF, Knauer Y, et al. Extreme hyperbilirubinemia and rescue exchange transfusion in California from 2007 to 2012. *J Perinatol* 2016;36:853–7.
15. Bjerre JV, Petersen JR, Ebbesen F. Surveillance of extreme hyperbilirubinaemia in Denmark. A method to identify the newborn infants. *Acta Paediatr* 2008;97:1030–4.
16. Christensen RD, Lambert DK, Henry E, et al. Unexplained extreme hyperbilirubinemia among neonates in a multihospital healthcare system. *Blood Cells, Molecules, and Diseases* 2013;50:105–9.
17. Ebbesen F, Andersson C, Verder H, et al. Extreme hyperbilirubinaemia in term and near-term infants in Denmark. *Acta Paediatr* 2005;1:59–64.
18. Eggert LD, Wiedmeier SE, Wilson J, et al. The effect of instituting a prehospital-discharge newborn bilirubin screening program in an 18-hospital health system. *Pediatrics* 2006;117:e855–e862.
19. Flaherman VJ, Kuzniewicz MW, Escobar GJ, et al. Total serum bilirubin exceeding exchange transfusion thresholds in the setting of universal screening. *J Pediatr* 2012;160:e791:796–800.
20. Gotink MJ, Benders MJ, Lavrijsen SW, et al. Severe neonatal hyperbilirubinemia in the Netherlands. *Neonatology* 2013;104:137–42.
21. Kuzniewicz MW, Escobar GJ, Wi S, et al. Risk factors for severe hyperbilirubinemia among infants with borderline bilirubin levels: a nested case-control study. *J Pediatr* 2008;153:234–40.
22. Manning D, Todd P, Maxwell M, et al. Prospective surveillance study of severe hyperbilirubinemia in the newborn in the UK and Ireland. *Arch Dis Child Fetal Neonatal Ed* 2007;92:F342–F346.
23. McGillivray A, Polverino J, Badawi N, et al. Prospective surveillance of extreme neonatal hyperbilirubinemia in Australia. *J Pediatr* 2016;168:e83:82–7.
24. Meberg A, Johansen KB. Screening for neonatal hyperbilirubinaemia and ABO alloimmunization at the time of testing for phenylketonuria and congenital hypothyreosis. *Acta Paediatr* 1998;87:1269–74.
25. National neonatal perinatal database. *National neonatal perinatal database: report: 2002–2003*. New Delhi: Nodal Centre, 2005.

26. Sgro M, Campbell D, Shah V. Incidence and causes of severe neonatal hyperbilirubinemia in Canada. *CMAJ* 2006;175:587–90.
27. Zoubir S, Mieth RA, Berrut S, et al. Incidence of severe hyperbilirubinaemia in Switzerland: a nationwide population-based prospective study. *Arch Dis Child Fetal Neonatal Ed* 2011;96:F310–F311.
28. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. *Pediatrics* 2004;114:297–316.
29. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. *Int J Epidemiol* 2007;36:666–76.
30. Wong WC, Cheung CS, Hart GJ. Development of a quality assessment tool for systematic reviews of observational studies (QATSO) of HIV prevalence in men having sex with men and associated risk behaviours. *Emerg Themes Epidemiol* 2008;5:23.
31. Lieb R. Population-Based Study. In: Gellman MD, Turner JR, eds. *Encyclopedia of Behavioral Medicine*. New York: NY: Springer New York, 2013:1507–8.
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177–88.
33. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
34. R: A language and environment for statistical computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing, 2013.
35. Bang AT, Bang RA, Baitule S, et al. Burden of morbidities and the unmet need for health care in rural neonates—a prospective observational study in Gadchiroli, India. *Indian Pediatr* 2001;38:952–65.
36. Olusanya BO, Akande AA, Emokpae A, et al. Infants with severe neonatal jaundice in Lagos, Nigeria: incidence, correlates and hearing screening outcomes. *Trop Med Int Health* 2009;14:301–10.
37. Le LT, Partridge JC, Tran BH, et al. Care practices and traditional beliefs related to neonatal jaundice in northern Vietnam: a population-based, cross-sectional descriptive study. *BMC Pediatr* 2014;14:264.
38. Wainer S, Parmar SM, Allegro D, et al. Impact of a transcutaneous bilirubinometry program on resource utilization and severe hyperbilirubinemia. *Pediatrics* 2012;129:77–86.
39. Ebbesen F, Bjerre JV, Vandborg PK. Relation between serum bilirubin levels $\geq 450 \mu\text{mol/L}$ and bilirubin encephalopathy: a Danish population-based study. *Acta Paediatr* 2012;101:384–9.
40. Kuzniewicz MW, Wickremasinghe AC, Wu YW, et al. Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns. *Pediatrics* 2014;134:504–9.
41. Ipek IO, Bozaykut A. Clinically significant neonatal hyperbilirubinemia: an analysis of 646 cases in Istanbul. *J Trop Pediatr* 2008;54:211–3.
42. Simiyu DE. Morbidity and mortality of neonates admitted in general paediatric wards at Kenyatta National Hospital. *East Afr Med J* 2003;80:611–6.
43. Ezeaka V, Ekure E, Iroha E, et al. Outcome of low birth weight neonates in a tertiary health care centre in Lagos, Nigeria. *Afr J Med Sci* 2004;33:299–303.
44. Mukhtar-Yola M, Iliyasu Z. A review of neonatal morbidity and mortality in Aminu Kano Teaching Hospital, northern Nigeria. *Trop Doct* 2007;37:130–2.
45. Subspecialty Group of Neonatology. Epidemiologic survey for hospitalized neonates in China. *China J Contemp Pediatr* 2009;11:15–20.
46. Kiliç S, Tezcan S, Taşçılar E, et al. Morbidity and mortality characteristics of infants hospitalized in the Pediatrics Department of the largest Turkish military hospital in 2001. *Mil Med* 2005;170:48–51.
47. Le L, Partridge J, Newman T. Causes of hyperbilirubinemia leading to exchange blood transfusion at the National Referral Hospital in Northern Vietnam: a preliminary case series. *Paper presented at: Society for Pediatric Research* 2009.
48. Kaini NR, Chaudhary D, Adhikary V, et al. Overview of cases and prevalence of jaundice in neonatal intensive care unit. *Nepal Med Coll J* 2006;8:133–5.
49. Seoud I, Abd El-Latif M, Abd El-Latif D. Neonatal jaundice in cairo university pediatric hospital. *J of Arab Child* 2007;18:65–74.
50. Newborn Health: The Issue. <http://www.savethechildren.org/> accessed 13 Dec 2016, 2016
51. Adebami O. Factors associated with the incidence of acute bilirubin encephalopathy in Nigerian population. *J Pediatric Neurology* 2011;9:347–53.
52. Eneh AU, Oruamabo RS. Neonatal jaundice in a special care baby unit (SCBU) in port harcourt, nigeria: a prospective study. *Port Harcourt Medical Journal* 2008;2:110–7.
53. Narang A, Gathwala G, Kumar P. Neonatal jaundice: an analysis of 551 cases. *Indian Pediatr* 1997;34:429–32.
54. National Neonatal Perinatal Database. Morbidity and mortality among outborn neonates at 10 tertiary care institutions in India during the year 2000. *J Trop Pediatr* 2004;50:170–4.
55. Salas AA, Mazzi E. Exchange transfusion in infants with extreme hyperbilirubinemia: an experience from a developing country. *Acta Paediatr* 2008;97:754–8.
56. Owa JA, Ogunlesi TA, Ogunlesi TA. Why we are still doing so many exchange blood transfusion for neonatal jaundice in Nigeria. *World J Pediatr* 2009;5:51–5.
57. Ogunlesi TA, Ogunfowora OB. Predictors of acute bilirubin encephalopathy among Nigerian term babies with moderate-to-severe hyperbilirubinemia. *J Trop Pediatr* 2011;57:80–6.
58. Agrawal VK, Shukla R, Misra PK, et al. Brainstem auditory evoked response in newborns with hyperbilirubinemia. *Indian Pediatr* 1998;35:513–8.
59. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischARGE hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. *Pediatrics* 1999;103:6–14.
60. Olusanya BO, Ogunlesi TA, Kumar P, et al. Management of late-preterm and term infants with hyperbilirubinemia in resource-constrained settings. *BMC Pediatr* 2015;15:39.
61. Farouk ZL, Muhammed A, Gambo S, et al. Follow-up of children with kernicterus in kano, nigeria. *J Trop Pediatr* 2017.
62. Olusanya BO, Somefun AO. Sensorineural hearing loss in infants with neonatal jaundice in Lagos: a community-based study. *Ann Trop Paediatr* 2009;29:119–28.
63. da Silva LP, Queiros F, Lima I. Etiology of hearing impairment in children and adolescents of a reference center APADA in the city of Salvador, state of Bahia. *Braz J Otorhinolaryngol* 2006;72:33–6.
64. Tikmani SS, Warraich HJ, Abbasi F, et al. Incidence of neonatal hyperbilirubinemia: a population-based prospective study in Pakistan. *Trop Med Int Health* 2010;15:502–7.
65. Adeolu AA, Arowolo OA, Alatise OI, et al. Pattern of death in a Nigerian teaching hospital: 3-decade analysis. *Afr Health Sci* 2010;10:266–72.
66. Mwaniki MK, Gatakaa HW, Mturi FN, et al. An increase in the burden of neonatal admissions to a rural district hospital in Kenya over 19 years. *BMC Public Health* 2010;10:1–13.
67. Iskander I, Gamaleldin R, El Houchi S, et al. Serum bilirubin and bilirubin/albumin ratio as predictors of bilirubin encephalopathy. *Pediatrics* 2014;134:e1330–e1339.
68. Emokpae AA, Mabogunje CA, Imam ZO, et al. Heliotherapy for Neonatal Hyperbilirubinemia in Southwest, Nigeria: A Baseline Pre-Intervention Study. *PLoS One* 2016;11:e0151375.
69. Olusanya BO, Emokpae AA, Zamora TG, et al. Addressing the burden of neonatal hyperbilirubinemia in countries with significant glucose-6-phosphate dehydrogenase deficiency. *Acta Paediatr* 2014;103:1102–9.
70. Ogunfowora OB. Community-related factors militating against effective management of neonatal jaundice in resource-limited settings. *Nigerian Medical Practitioner* 2016;69.
71. Mukhopadhyay K, Chowdhary G, Singh P, et al. Neurodevelopmental outcome of acute bilirubin encephalopathy. *J Trop Pediatr* 2010;56:333–6.
72. Ayanniyi O, Abdulsalam KS. Profile of Children with Cerebral Palsy Attending Out-patient Physiotherapy Clinics in Southwest Nigeria. *AJPARS* 2015;7:32–9.
73. Ogunlesi TA, Dedeke IO, Adekanmbi AF, et al. The incidence and outcome of bilirubin encephalopathy in Nigeria: a bi-centre study. *Niger J Med* 2007;16:354–9.
74. Öztürk A, Demirci F, Yavuz T, et al. Antenatal and delivery risk factors and prevalence of cerebral palsy in Düzce (Turkey). *Brain Dev* 2007;29:39–42.
75. Lawn JE, Blencowe H, Oza S, et al. Every Newborn: progress, priorities, and potential beyond survival. *Lancet* 2014;384:189–205.
76. Arnold G, Thein AA, Trevisanuto D, et al. Evaluation of a simple intervention to reduce exchange transfusion rates among inborn and outborn neonates in Myanmar, comparing pre- and post-intervention rates. *BMC Pediatr* 2015;15:216.
77. Slusher TM, Olusanya BO, Vreman HJ, et al. A randomized trial of phototherapy with filtered sunlight in african neonates. *N Engl J Med* 2015;373:1115–24.
78. Sgro M, Kandasamy S, Shah V, et al. Severe neonatal hyperbilirubinemia decreased after the 2007 canadian guidelines. *J Pediatr* 2016;171:43–7.

79. World Health Organization. Newborn: reducing mortality, 2014. <http://www.who.int/mediacentre/factsheets/fs333/en/> (accessed 15 Aug 2017).
80. Essential Care for Every Baby - AAP.org. 2017 <https://www.aap.org/en-us/advocacy.babies./Essential-Care-Every-Baby.aspx> (accessed 2 Sep 2017).
81. Greenland S. Can meta-analysis be salvaged? *Am J Epidemiol* 1994;140:783–7.
82. Independent States of the World. <http://www.nationsonline.org/>
83. Bhutani VK, Johnson L. A proposal to prevent severe neonatal hyperbilirubinemia and kernicterus. *J Perinatol* 2009;29(Suppl 1):S61–S67.